ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 1, 2017
Big Pharma, Big Dividends: Earnings Update Featuring Eli Lilly, Bristol-Myers Squibb, and AbbVie
Image Source: Drugs.com. Let’s dive into some recent developments and earnings reports from three big pharma players with meaningful income considerations.
May 1, 2017
Dividend Increases/Decreases for the Week Ending Apr 28
Let's take a look at companies raising/lowering their dividends this week.
Apr 28, 2017
More First-Quarter Earnings Flying In: GM, Ford, Big Oil and More
Image Source: General Motors. GM’s dividend yield and valuation opportunity are incredible, while Microsoft’s free cash flow generation and solid net cash position speak to tremendous dividend strength. We liked what we saw out of Union Pacific during the first quarter, and you have to be aware of Big Oil’s bloated balance sheets. All of this and more included in this piece.
Apr 25, 2017
Healthcare Earnings Update Featuring Johnson and Johnson, Cardinal Health and Abbott Labs
Image Source: Johnson & Johnson. The upcoming deluge of earnings over the next couple of weeks offers a glimpse into the ongoing business prospects for the various companies in our coverage universe. Let’s discuss the recent news release of a few prominent names in the healthcare industry.
Apr 20, 2017
Reflecting on Recent Report Updates: Favorites in an Overheated Market and Other Themes
It’s been some time since we’ve updated members on our recent fair value estimate updates. Let’s take a look at the opportunities that exist in some of our favorite portfolio holdings, as well as some key themes driving recent fair value estimate changes across our coverage universe.
Apr 17, 2017
Which Mid-Stage Biotech Can Grow Into the Next Large Cap Biotech Behemoth?
Image Source: Steven Depolo. The biotech field is on the cutting edge of scientific research. The production of new therapies often positively affects the share price of these innovative companies as long-term revenue and earnings expectations become embedded in the stock price. Let’s take a look at several mid-stage biotechs that may grow into dominant players.
Apr 13, 2017
Trash As A Source of Cash and 2 New Additions to the Best Ideas Newsletter Portfolio
Image Source: thetaxhaven. We’re making a number of adjustments to the Best Ideas Newsletter portfolio.
Apr 11, 2017
Three Notable Pending FDA Approvals
Image Source: Brandon Giesbrecht. The final step of the drug approval process is the filing of a new drug application (NDA), when the FDA assesses trial results before deciding if the treatment warrants marketing approval. A delay or rejection can have a meaningful impact on the equity price, so let’s dig into a few notable upcoming decisions.
Apr 7, 2017
Panera Eaten Up; SeaDrill’s End, Cisco’s Dividend Hike and Much More
Let’s go around the horn with recent investment-related news. Let’s say goodbye to Panera, talk about SeaDrill’s infamous demise, follow up on the Coach dividend saga, address Cisco’s payout strength and attractive valuation, update readers on Medtronic’s portfolio optimization initiatives, and try to reason through Tesla’s recent price surge.
Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.